Get your patients started on AJOVY. Begin here

Resources for AJOVY


Videos from AJOVY: The Expert Series

Have patients new to preventive therapy? Dr Cooper discusses what to look for and why you should consider starting your patients on preventive therapy with AJOVY.
Were you referred a patient for the management for their migraine? See why Dr Ailani thinks AJOVY may be an appropriate treatment option for your patients.
Dr Sacco discusses common issues to consider when choosing a preventive therapy, as well as the safety profile of AJOVY.
Listen to Dr Torphy review data related to the long-acting effect of AJOVY.1*

*”Long-acting” and “lasting protection” defined as reduction in monthly average migraine or headache days (chronic migraine: 4.6 and 4.3 fewer headache days of at least moderate severity with monthly and quarterly dosing, respectively, vs 2.5 with placebo; episodic migraine: 3.7 and 3.4 fewer migraine days with monthly and quarterly dosing, respectively, vs 2.2 with placebo) measured over a 12-week period following a monthly 225 mg SC dose or quarterly 675 mg (225 mg x 3) SC dose.1

This program was developed in conjunction with and sponsored by Teva Pharmaceuticals. Physicians received compensation for participation in this program

More videos for AJOVY

Watch MOA video of AJOVY

AJOVY Autoinjector administration video

What to explore next